COYA

Over the past six months, Coya Therapeutics reported its First Quarter 2026 Financial Results and provided a corporate update on May 12, 2026, the same day the FDA granted Fast Track Designation for COYA 302 for ALS. On June 18, 2026, the company announced it would present the ALSTARS trial design at the ENCALS 2026 Meeting. On August 11, 2026, it reported its Second Quarter 2026 Financial Results and a corporate update. A preclinical study demonstrating the immunomodulatory effects of COYA 303 was published on September 8, 2026, and on September 15, 2026, the company announced the enrollment of the 100th participant in its Phase 2/3 ALSTARS trial for COYA 302. Throughout this period, analysts like D. Boral Capital and Chardan Capital maintained 'Buy' recommendations, contributing to a consensus 'Moderate Buy' rating for COYA from analysts.